

ASX / Media Release

27 February 2013

CIRCADIAN COMMENCES WORLDWIDE MARKETING & SALES OF UNIQUE VEGF-C & VEGF-D PRODUCTS AS RESEARCH REAGENTS.

- **Unique products arising from ongoing therapeutic development programs**
- **Important step in our strategy to increase Circadian's revenues**
- **Product range expected to expand over next 3-6 months**

Circadian Technologies (ASX.CIR; OTCQx:CKDXY) has today launched a range of unique VEGF-C and VEGF-D Vegenics branded products as research reagents which it will sell directly to the worldwide life science research community.

Circadian's will initially offer versions of recombinant human VEGF-D and VEGF-C that have been developed as part of Circadian's ongoing therapeutic development programs. These products have improved and complementary properties to available VEGF-C and VEGF-D research reagents and will expand the range of reagents currently available to investigators researching angiogenesis and lymphangiogenesis. Circadian expects to add further VEGF-C and VEGF-D Vegenics branded products to its catalogue in the next 3-6 months.

Robert Klupacs, CEO of Circadian said "Our goal is to further enhance scientific research by providing high quality, unique and specialised reagents. We are delighted to be able to provide reagents that leverage expertise gained as part of our therapeutic research programs. We believe that they will and greatly assist in the further understanding of VEGF-C and/or VEGF-D in biology."

He added "We anticipate that the launch of these reagents will be the first of many to become available to the research community from the portfolio of products in development by Circadian and our partners. Direct marketing of research reagents is an important part of our ongoing strategy to increase revenues into the Company. Given the ever increasing number of laboratories studying angiogenesis and lymphangiogenesis worldwide, and the need to provide investigators with highly specialised reagents, we anticipate that our research reagents will become an important ongoing revenue source which we will utilise to support our ongoing drug development activities."

Products can be ordered directly through www.vegenics.com. Orders will be delivered within approximately 48-72 hrs to researchers worldwide and within 24-48 hours to Australian researchers.

Company Enquiries:

Robert Klupacs
Managing Director - Circadian
Tel: +61 (0) 3 9826 0399
robert.klupacs@circadian.com.au

Media Enquiries – International:

Lauren Glaser
The Trout Group LLC
251 Post Street, Suite 412
San Francisco, CA 94108
Tel +1 215 740 8468
lglaser@troutgroup.com

About Circadian Technologies Limited

Circadian (ASX:CIR; OTCQX:CKDXY) is a biologics drug developer focusing on cancer, cancer related and ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around Vascular Endothelial Growth Factor (VEGF)-C and -D. The applications for the VEGF technology, which functions in regulating blood and lymphatic vessel growth, are substantial and broad. Circadian's internal product development programs are primarily focused on developing VGX-100 (a human antibody against VEGF-C) as a treatment for lymphedema resulting from breast cancer treatment and solid tumours, in particular glioblastoma and colorectal cancer, as well as developing VGX-300 (soluble VEGFR-3) for 'back of the eye' disease such as wet Age Related Macular Degeneration. Circadian has also licensed rights to some parts of its intellectual property portfolio for the development of other products to ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, including the anti-lymphatic antibody-based drug IMC-3C5 targeting VEGFR-3.

Forward-looking statement

Certain statements in this ASX announcement may contain forward-looking statements regarding Company business and the therapeutic and commercial potential of its technologies and products in development. Any statement describing Company goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the process of discovering, developing and commercialising drugs that can be proven to be safe and effective for use as human therapeutics, and in the endeavor of building a business around such products and services. Circadian undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Actual results could differ materially from those discussed in this ASX announcement.